Finerenone Dosing, Monitoring, and Contraindications
For an adult with CKD stage 2-4, type 2 diabetes, albuminuria, eGFR ≥20 mL/min/1.73 m², and serum potassium ≤4.8 mmol/L, initiate finerenone at 10 mg daily if eGFR is 25-59 mL/min/1.73 m² or 20 mg daily if eGFR ≥60 mL/min/1.73 m², with mandatory potassium monitoring at 1 month, then every 4 months thereafter. 1
Patient Eligibility Criteria
This patient meets all criteria for finerenone initiation based on KDIGO 2024 guidelines 1:
- Type 2 diabetes with CKD (Grade 2A recommendation)
- eGFR >25 mL/min/1.73 m² (minimum threshold)
- Albuminuria >30 mg/g despite maximum tolerated RAS inhibitor
- Serum potassium ≤4.8 mmol/L (mandatory pre-treatment requirement)
The guidelines emphasize that nonsteroidal MRAs are most appropriate for adults at high risk of CKD progression and cardiovascular events, demonstrated by persistent albuminuria despite standard-of-care therapies 1.
Initial Dosing Algorithm
The starting dose is determined solely by eGFR at initiation 1:
- eGFR 25-59 mL/min/1.73 m²: Start 10 mg once daily
- eGFR ≥60 mL/min/1.73 m²: Start 20 mg once daily
This eGFR-based dosing strategy accounts for the 40% increase in finerenone exposure seen with moderate renal impairment, though this does not require dose adjustment per se since the starting dose already incorporates this consideration 2.
Dose Titration Protocol
After 1 month of treatment, if serum potassium remains ≤4.8 mmol/L and eGFR is stable, increase from 10 mg to 20 mg daily 1, 3. This titration strategy was validated in the FIGARO-DKD trial, where dose escalation was encouraged after 1 month provided potassium levels were appropriate 3.
Mandatory Potassium Monitoring Schedule
Critical monitoring timeline 1:
- At 1 month after initiation: Check serum potassium
- Every 4 months thereafter: Ongoing potassium monitoring
- With any dose adjustment: Recheck potassium
Potassium-Based Management Algorithm 1
| Potassium Level | Action |
|---|---|
| ≤4.8 mmol/L | Continue current dose OR increase 10 mg to 20 mg daily |
| 4.9-5.5 mmol/L | Continue current dose (10 or 20 mg); monitor K+ every 4 months |
| >5.5 mmol/L | HOLD finerenone; adjust diet/medications; recheck K+; restart at 10 mg daily when K+ ≤5.0 mmol/L |
Common pitfall: The 4.9-5.5 mmol/L range does NOT require dose reduction or discontinuation—continue therapy with regular monitoring 1. This differs from traditional approaches with steroidal MRAs and reflects finerenone's more favorable hyperkalemia profile.
Contraindications
Absolute contraindications:
- Serum potassium >4.8 mmol/L at baseline (cannot initiate) 1, 3
- eGFR <25 mL/min/1.73 m² 1
- Concomitant strong CYP3A4 inhibitors (contraindicated) 2
Relative contraindications requiring caution:
- Moderate or strong CYP3A4 inducers (should be avoided) 2
- Moderate CYP3A4 inhibitors (require potassium monitoring during initiation/adjustment) 2
Combination Therapy Considerations
Finerenone may be added to RAS inhibitors and SGLT2 inhibitors 1. The guidelines explicitly state this triple therapy approach is appropriate for adults with T2D and CKD 1. Real-world data shows finerenone is typically initiated as add-on therapy: 58.5% with RASi, 28.0% with SGLT2i, and only 8.5% as monotherapy 4.
Important sequencing note: While simultaneous initiation with SGLT2i may be appropriate in selected high-risk patients, this is not a universal default strategy 5. The priority is ensuring baseline potassium and kidney function are appropriate before adding finerenone.
Expected Clinical Effects
Albuminuria reduction: Expect approximately 37-40% reduction in UACR after 6 months of treatment 6, 7, 8. Patients experiencing an initial eGFR dip ≥20% may show even greater albuminuria reduction (around 43%) 6.
eGFR trajectory: A 9.5% decline in eGFR at 1 month is expected, followed by stabilization at 3 and 6 months 6. This initial dip should NOT prompt discontinuation—it represents hemodynamic adaptation similar to that seen with RAS inhibitors 1.
Safety Profile
Hyperkalemia incidence: 17-18% of patients develop hyperkalemia (K+ >5.5 mmol/L), but discontinuation rates are low (1.5%) and hospitalizations rare (0.9%) 6, 9. The highest risk occurs in patients with eGFR <30 mL/min/1.73 m² (37.5% incidence) 7.
Discontinuation rates: In real-world practice, 56% of patients remain on finerenone at 12 months, with only 10% discontinuing due to adverse events 4, 6.
Key Clinical Pearls
- Do not withhold finerenone for potassium 4.9-5.5 mmol/L—this is a continuation range, not a stopping range 1
- The initial eGFR decline is expected and not an indication to stop 1, 6
- Finerenone can be taken with or without food 2
- Monitor for CYP3A4 drug interactions, particularly with moderate inhibitors (azole antifungals, diltiazem, verapamil) which require enhanced potassium monitoring 2
- Dose titration from 10 to 20 mg occurs in only 16.7% of real-world patients, suggesting conservative clinical practice 4